

FOR IMMEDIATE RELEASE

**ORPHAN DRUG COMPANY NAMES ENVENOMATION EXPERT AS NEW
PRESIDENT OF RARE DISEASE THERAPEUTICS**

August 21, 2019

Franklin, TN – [Rare Disease Therapeutics, Inc.](#) (RDT) recently appointed well-known toxicologist and envenomation expert Jude McNally as its president. As president, McNally will oversee all of RDT's national and international business affairs. RDT, known as America's first exclusively orphan drug company, partners with [innovative drug manufacturers](#) from around the world to bring medicine to patients with rare medical conditions. McNally spent 10 years as RDT's medical science liaison, and his promotion was timed to coincide with the launch of RDT's new North American rattlesnake antivenom.

Before coming to RDT, McNally spent 25 years as the managing director of the [Arizona Poison and Drug Information Center in Tucson](#). There he participated in drug research and consulted on pharmacy and toxicology matters. "McNally's experience with medicine, patient care, and drug development is vast. He has been involved in the research of every antivenom approved in America over the last 30 years," commented Milton Ellis, Chairman and founder of RDT.

RDT's [products](#) extend beyond antivenoms and include oncology and hematology drugs for patients with rare medical conditions. Treating people with rare medical conditions (known as "orphan" diseases) has been [RDT's sole focus](#) since 1991. Orphan diseases are often overlooked by traditional pharmaceutical companies. McNally points out,

///more///

“This low volume/low return environment just isn’t attractive to a stockholder interested in quarterly snapshots of growth. Serving our segment of patients can only be done by a long-term commitment fueled by passion. That’s rare, and that’s what we’re all about.”

Ellis concludes, “McNally’s drive to continually push for better medicines, his experience, and his vision are exactly what we need to help as many patients as we can.”

MORE ABOUT RARE DISEASE THERAPEUTICS, INC.

Founded in 1991, Rare Disease Therapeutics, Inc. (RDT) is America’s first company to focus solely on orphan drugs. Based in Franklin, Tennessee, RDT specializes in the development, registration, marketing and distribution of drugs for rare disorders. RDT conducts business in the Americas as a privately-held entity, and globally through a consortium of similarly focused companies. To learn more, visit: www.raretx.com

CONTACT

Rare Disease Therapeutics, Inc., 2550 Meridian Blvd, Suite 150, Franklin, TN 37067

Tel: 1 (615) 399-0700

Email: media@raretx.com